About
Qvanteq AG develops novel biofunctional surfaces to address and overcome the clinical adverse effects of today's medical devices and vascular stents. Qvanteq's Qstent technology stands for reduced thrombus formation and fast healing. Qvanteq AG was founded in early 2009 and is held by private investors. Qvanteq is ISO 13485 certified. Qvanteq is a spin-off company from the Swiss Federal Institute of Technology (ETH) Zurich. The company was awarded with the CTI start-up label in 2012.
Technologies
Gmail
Google Apps
Apache
WordPress.org
Bootstrap Framework
Mobile Friendly
Data Analytics
IoT
Remote
Phoenix
Vincere
AI
Node.js
Android
Keywords
medical equipment manufacturing
vascular implant technology
medical equipment and supplies manufacturing
blood clot prevention
surface modification
blood cascade inhibition
blood compatibility testing
pro-healing surfaces
blood-material interaction
thrombus formation
biocompatibility
surface-treated implants
hemocompatibility
thrombogenicity reduction
blood-material interface
blood-material interface optimization
blood flow optimization
medical devices
antithrombotic surface
protein adsorption
blood protein adsorption
blood coagulation cascade
endothelialization
blood flow studies
medical device innovation
b2b
titanium alloys
blood-contact biomaterials
blood surface engineering
blood coagulation
Company Information
-
Employees 3
-
Founded 2009
-
Total Funding $4359207
Location
1 Technoparkstrasse, Zurich, Zurich, Switzerland, 8005
